SARS-COV-2 VIRUS SPIKE PROTEIN

Summary

Sars-Cov-2 Virus Spike Protein (CHEMBL6068382) is an approved vaccine component; indicated across 2 conditions including covid-19.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Vaccine component
• Indications: 2 conditions
• Clinical trials: 2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL6068382
Name	SARS-COV-2 VIRUS SPIKE PROTEIN
Type	Vaccine component
Max phase	4

Also known as: Nuvaxovid, Sars-cov-2 virus spike protein, Vidprevtyn beta, SARS-COV-2 VIRUS SPIKE PROTEIN

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
COVID-19	4	MONDO:0100096	MONDO:0100096

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE4	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07051031	PHASE4	ACTIVE_NOT_RECRUITING	COVID-19 Reactogenicity
NCT05142319	PHASE4	COMPLETED	Efficacy of Different COVID-19 Vaccine Combinations in Inducing Long-term Humoral Immunity [PRIBIVAC]

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).